Schizophrenia, Metabolic Syndrome and the Opportunity for developing Pharmacist-led Toolkit for Education and Metabolic Syndrome Screening (EMESYS): A Review

• Main Authors: Julaeha, -, Umi Athiyah, -, Verra Yuliana, -, JP Ayuningtyas, -, Andi Hermansyah, -
• Format: Article PeerReviewed
• Language: English; English; English; English
• Published: Advanced Scientific Research 2021
• Subjects: R Medicine; RS Pharmacy and materia medica; RS1-441 Pharmacy and materia medica; RS200-201 Pharmaceutical dosage forms
• Online Access: https://repository.unair.ac.id/124449/1/Bukti%20Artikel%20C-22.pdf; https://repository.unair.ac.id/124449/4/Bukti%20Validasi%20dan%20Penilaian%20Karil%20C-22.pdf; https://repository.unair.ac.id/124449/3/Bukti%20Similarity%20C-22.pdf; https://repository.unair.ac.id/124449/2/Bukti%20Korespondensi%20C-22.pdf; https://repository.unair.ac.id/124449/; http://www.ijpronline.com/ViewArticleDetail.aspx?ID=21175; https://doi.org/10.31838/ijpr/2021.13.02.154
• Institution: Universitas Airlangga

The use of Second-Generation Antipsychotic (SGA) medications has been common for patients with Schizophrenia. However, this comes with an increased risk of metabolic syndrome event. Such condition has been a concern given the long-term period for therapy. This highlights an untapped opportunity for pharmacists in preventing metabolic syndrome events and educating patients about the risk of their treatment. A toolkit for supporting such an extended pharmacist's role is essential due to the paucity of a practical tool. This study provides a review about the use of SGAs, the potential of metabolic syndrome events, and the development of a toolkit supporting the pharmacist's role in treating the patient with mental health issues, including Schizophrenia. Treatment of Schizophrenia and metabolic syndrome is indeed challenging. Nevertheless, the toolkit might facilitate the interaction between pharmacist and patient, implying better outcomes might be achieved in the long-term treatment.